...
首页> 外文期刊>Toxicology Reports >Mucoadhesive formulation of Bidens pilosa L. (Asteraceae) reduces intestinal injury from 5-fluorouracil-induced mucositis in mice
【24h】

Mucoadhesive formulation of Bidens pilosa L. (Asteraceae) reduces intestinal injury from 5-fluorouracil-induced mucositis in mice

机译:Bidens pilosa L.(Asteraceae)粘膜粘着剂可减轻小鼠5-氟尿嘧啶引起的粘膜炎对肠道的伤害

获取原文
           

摘要

Gastrointestinal mucositis induced during cancer treatment is considered a serious dose-limiting side effect of chemotherapy and/or radiotherapy. Frequently, interruption of the cancer treatment due to this pathology leads to a reduction in cure rates, increase of treatment costs and decrease life quality of the patient. Natural products such as Bidens pilosa L. (Asteraceae), represent a potential alternative for the treatment of mucositis given its anti-inflammatory properties. In this study, B. pilosa glycolic extract was formulated (BPF) with poloxamer, a mucoadhesive copolymer, was used for treatment of 5-fluorouracil (5-FU)-induced mucositis in mice. As expected, animals only treated with 5-FU (200mg/kg) presented marked weight loss, reduction of intestinal villi, crypts and muscular layer, which was associated with severe disruption of crypts, edema, inflammatory infiltrate and vacuolization in the intestinal tissue, as compared to the control group and healthy animals only treated with BPF. On the other hand, the treatment of intestinal mucositis-bearing mice with BPF (75, 100 or 125mg/kg) managed to mitigate clinical and pathologic changes, noticeably at 100mg/kg. This dose led to the restoration of intestinal proliferative activity through increasing Ki-67 levels; modulated the expression of Bax, Bcl2 and p53 apoptotic markers protecting intestinal cells from cell death. Moreover, this treatment regulated lipid peroxidation and inflammatory infiltration. No acute toxic effects were observed with this formulation. This work demonstrated that BPF was safe and effective against 5-FU-induced intestinal mucositis in mice. Additional studies are already in progress to further characterize the mechanisms involved in the protective effects of this technological formulation toward the development of a new medicine for the prevention and treatment of intestinal injury in patients undergoing chemotherapy/radiotherapy.
机译:在癌症治疗期间诱发的胃肠道粘膜炎被认为是化学疗法和/或放射疗法的严重的剂量限制副作用。通常,由于这种病理导致的癌症治疗的中断导致治愈率的降低,治疗费用的增加和患者的生活质量的降低。鉴于其抗炎特性,诸如Bidens pilosa L.(菊科)之类的天然产品是治疗粘膜炎的潜在替代品。在这项研究中,毛果双歧杆菌的乙醇提取物与泊洛沙姆(一种粘膜粘附性共聚物)一起配制(BPF),用于治疗5-氟尿嘧啶(5-FU)诱导的小鼠粘膜炎。正如预期的那样,仅接受5-FU(200mg / kg)治疗的动物体重明显减轻,肠绒毛,隐窝和肌肉层减少,这与隐窝的严重破坏,水肿,炎性浸润和肠道组织空泡有关,与对照组和仅用BPF治疗的健康动物相比。另一方面,用BPF(75、100或125mg / kg)治疗肠粘膜炎小鼠设法减轻临床和病理变化,明显为100mg / kg。该剂量可通过增加Ki-67水平来恢复肠道增殖活性。调节Bax,Bcl2和p53凋亡标记的表达,保护肠道细胞免受细胞死亡。而且,这种治疗调节脂质过氧化和炎性浸润。用该制剂未观察到急性毒性作用。这项工作证明BPF对小鼠中5-FU引起的肠粘膜炎是安全有效的。已经进行了进一步的研究,以进一步表征该技术配方对开发用于预防和治疗接受化学疗法/放射疗法的患者肠道损伤的新药的保护作用的机制。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号